Non-randomised trial, 2023
Do anti-CGRP antibodies work the same for period-related migraines as other migraines?
Yes. Both period-related and non-period-related migraine days improved equally when treated with anti-CGRP antibodies.
What they did
Women with migraine tracked migraine days using electronic diaries during one baseline month and 6 months of treatment with either erenumab or fremanezumab.
What they found
Treatment reduced migraine days similarly whether they occurred around the menstrual window or at other times (odds ratio 0.44, 95% CI 0.38-0.51).
What it means for you
Anti-CGRP antibodies reduce menstrual-related migraines as effectively as other migraines. Main limit: single-arm study with no comparison group.
0.44
Odds ratio for migraine days under treatment
6
Months of treatment
0.38-0.51
95% confidence interval
About the study
- Original title
- Both perimenstrual and nonperimenstrual migraine days respond to anti-calcitonin gene-related peptide (receptor) antibodies
- Authors
- Verhagen IE, de Vries Lentsch S, van der Arend BWH et al.
- Journal
- European journal of neurology
- Year
- 2023
- Study design
- Non-randomised trial
- What was tested
- erenumab or fremanezumab (anti-CGRP antibodies)
- Open access
- Yes
- Read the paper
- doi.org/10.1111/ene.15794
Topics
Related studies
Systematic review, 2023
What hormonal treatments have been tested for PMDD, menstrual migraine, and catamenial epilepsy?
Cohort study, 2022
Can women accurately tell if they have period-related migraines, or do they need to track them?
Guideline, 2021
How should migraine be managed in women, particularly menstrual migraine?
Randomised trial, 2016
Does telcagepant prevent migraines during the menstrual period?
Randomised trial, 2014
Does the combination of sumatriptan and naproxen sodium reduce menstrual symptoms and migraine?
Randomised trial, 2005
Does sumatriptan work for migraines around the menstrual cycle?